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Abstract
Background—Colorectal cancer (CRC) incidence and mortality rates vary across race/ethnicity. 
Socioeconomic status (SES) also influences CRC rates; however, these associations might be 
inconsistent across racial/ethnic groups and tumor subsite. We examined associations between 
area-level SES and CRC incidence and mortality in a population-based registry study of non-
Hispanic Whites, African Americans, Hispanics, and Asians/Pacific Islanders from California.
Methods—Data on 52,608 incident CRC cases (1998–2002) and 14,515 CRC deaths (1999–
2001) aged ≥50 years were obtained from the California Cancer Registry. Based on 2000 U.S. 
Census data, each cancer case and death was assigned a multidimensional census tract-level SES 
index. SES-specific quintiles of CRC incidence and mortality rates, incidence rate ratios (IRR) and 
mortality rate ratios, and 95% confidence intervals (CI) were estimated. Analyses were stratified 
by anatomical site, including left- versus right-sided tumors, race/ethnicity, and stage of disease.
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Results—Overall CRC incidence and SES did not show a clear association, yet patterns of 
associations varied across tumor subsite and race/ethnicity. Positive associations between SES and 
CRC incidence were found in Hispanics [SES Q5 v. Q1: IRR = 1.54, CI = 1.39–1.69], irrespective 
of the subsite. For Whites [SES Q5 v. Q1: IRR = 0.80, CI = 0.77–0.83], and African Americans 
[SES Q5 v. Q1: IRR = 0.83, CI = 0.70–0.97] inverse associations were observed, predominantly 
for left-sided tumors. Mortality rates declined with increasing SES in Whites, whereas in 
Hispanics mortality rates significantly increased with SES.
Conclusions—Our findings show that SES differences in CRC incidence and mortality vary 
considerably across anatomical subsite and race/ethnicity.
Impact—Studies combining area- and individual-level SES information are warranted.
Introduction
Colorectal cancer (CRC) is the third most common cancer in the United States (1, 2), 
accounting for approximately 10% of newly diagnosed cancers and 9% of cancer deaths (1). 
Incidence and mortality rates of CRC vary markedly across racial/ethnic groups. In the 
United States, African Americans and non-Hispanic Whites experience the highest incidence 
and mortality rates of CRC with Asians/Pacific Islanders and Hispanics having lower rates 
(2). Socioeconomic status (SES) has been inconsistently associated with incidence rates of 
CRC in the United States (3) with variable associations across racial/ethnic groups (4, 5). 
Lower SES has been consistently linked to higher mortality rates for CRC (3), yet less is 
known about how this relationship differs across racial/ethnic groups.
Over the past 2 decades, a shift in incidence toward more right-sided (ascending and 
transverse) than leftsided (descending and sigmoid) colon cancer has been reported (6–8). 
This has been attributed to differences in clinical and epidemiologic characteristics, 
molecular and genetic factors, and the use of colonoscopy and screening (7, 9–13). 
Furthermore, endoscopy screening for CRC has been positively associated with education, 
income, and health insurance coverage (14–16). Whether SES impacts the distribution of 
left- and right-sided colon cancer, particularly among racial/ethnic groups, is not well 
understood and has yet to be studied.
To further understand SES-related disparities in CRC, we examined the association between 
SES and incidence and mortality rates of CRC in a large, population-based study of CRC 
from the ethnically diverse state of California. In particular, we focused on examining the 
differences in these rates across racial/ethnic groups and tumor subsite.
Materials and Methods
Study population
Incident first primary cases of invasive CRC (n = 58,897) diagnosed from January 1998 
through December 2002 and CRC deaths (n = 15,546) that occurred from January 1999 
through December 2001 were identified by the California Cancer Registry (CCR), 
comprising 3 registries that are part of the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) program (Greater Bay Area Cancer Registry, Los 
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Angeles Cancer Surveillance Program, Cancer Registry of Greater California). These 5-year 
pericensal incidence and 3-year mortality periods were based on the availability of the 
appropriate population estimates to be used as denominators for rate calculations at the 
census tract level, based on 2000 Census data. For incident cases of CRC, data on age at 
cancer diagnosis, sex, race/ethnicity, residential address at diagnosis, and tumor subsite, 
stage, and grade were collected from medical records. For CRC deaths, age, sex, race/
ethnicity, and residential address at death were abstracted from death records; information 
on tumor subsite was not available. Race/ethnicity was classified as 5 mutually exclusive 
groups: (i) non-Hispanic African American, (ii) non-Hispanic Asian/Pacific Islander, (iii) 
Hispanic (of any race), (iv) non-Hispanic White, and (v) other/unknown. Tumor subsite was 
classified according to the International Classification of Diseases for Oncology, Second 
Edition with right colon cancer (cecum, appendix, ascending colon, hepatic flexure, 
transverse colon; C18.0–C18.4), left colon cancer (splenic flexure, descending colon, 
sigmoid; C18.5–18.7), rectal cancer (rectal sigmoid junction, rectum; C19.9 and C20.9), and 
other (C18.8–C18.9; overlapping lesions and not specified). Tumor stage was categorized as 
localized, regional/metastasized, or not abstracted/unknown. Because of low numbers of 
cases of “other” subsite (n = 2,251) and of unknown stage (n = 5,958), these cancers were 
omitted from site- and stage-specific analyses, respectively. For the present study, CRC 
patients aged less than 50 years at diagnosis and death (5,892 incident cases and 997 deaths) 
were excluded to focus on more sporadic forms of CRC. Those with other/unknown race/
ethnicity (397 cases and 34 deaths) were also excluded, resulting in a study population of 
52,608 incident CRC cases (1998-2002) and 14,515 CRC deaths (1999-2001).
SES and population data
Residential addresses of the cancer cases and deaths were geo-coded to the census tract 
level, an area covering about 4,000 residents, and linked to SES characteristics from the U.S. 
Census Bureau for these census tracts (17). Patients with unknown census tract of residence 
were randomly allocated to census tracts within their county of residence.
A previously developed composite score of SES was used, created by principal component 
analysis based on 7 SES indicators from census data: (i) education (18); (ii) median 
household income; (iii) percentage living 200% below poverty level; (iv) percentage of blue-
collar workers; (v) percentage older than 15 years in workforce, without job; (vi) median 
rent; and (vii) median house value (19). Each census tract was assigned this composite score 
and categorized in quintiles based on the statewide distribution. Supplementary Table S1 
(20) shows the distribution of the 7 census-based indicator variables of SES and the racial/
ethnic distribution for each SES quintile. In the lowest SES quintile (Q1), the mean years of 
education was 11 years in comparison to 15 years in the highest quintile (Q5); the median 
household income was $28,335 versus $89,254 in Q1 v. Q5, respectively. Population data 
from age-, sex-, and race-specific population counts for census tracts, were obtained from 
the modified age, race, sex, and Hispanic origin files from the 2000 U.S. census and used as 
the denominator in rate calculation. Because population estimates for census tracts were not 
available for intercensal years, the 2000 population counts were multiplied by 5 to estimate 
the total population at risk for the 5-year period of incidence and by 3 to estimate the 3-year 
period of mortality.
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Statistical analysis
CRC incidence and mortality rates were calculated per 100,000 individuals and age-adjusted 
to the 2000 U.S. standard population. SES quintile-specific incidence rate ratios (IRR) and 
mortality rate ratios (MRR) of CRC and 95% confidence intervals (CI) were estimated. 
Stratification analyses were conducted to examine consistency of effects across anatomical 
site, tumor subsite (left- vs. right-sided tumors for IRR only), race/ethnicity, and stage at 
diagnosis (IRR only). All analyses were conducted using SEER*Stat, version 6.3.4.
Results
SES and CRC incidence
Table 1 shows the characteristics of the 52,608 invasive incident CRC cases diagnosed from 
1998 through 2002. The largest proportion of cases were located in the right colon (n = 
20,560; 39.1%) in comparison to the left colon (n = 14,969; 28.5%) and rectum (n = 14,828; 
28.2%). A total of 55% of the cases had regional/metastasized disease and 58% were 
moderately differentiated with similar proportions across tumor subsites. About 22% of 
CRC cases were in the highest SES quintile, whereas 13.7% of CRC cases were in the 
lowest SES quintile.
There was no clear association between incidence rates of CRC and SES quintiles (Table 2). 
Incidence rates for right-sided colon cancer were slightly elevated in the highest SES 
quintile in comparison to the lowest quintile (IRRSES Q5 v. Q1 = 1.09; 95% CI: 1.04–1.14). 
For left colon cancer, rates were reduced for the highest than the lowest quintile 
(IRRSES Q5 v. Q1 = 0.93; 95% CI: 0.88–0.98) and among rectal cancer cases, no clear 
association was observed.
Significantly reduced incidence rates for CRC were associated with higher SES for non-
Hispanic Whites (IRRSES Q5 v. Q1 = 0.80; 95% CI: 0.77–0.83) and African Americans 
(IRRSES Q5 v. Q1 = 0.83; 95% CI: 0.70–0.97; Table 2). SES differentials were strongest 
among Hispanics, with incidence rates of CRC significantly elevated among those in higher 
levels of SES in comparison to those in low levels of SES (IRRSES Q5 v. Q1 = 1.54; 95% CI: 
1.39-1.69). Among Asians/Pacific Islanders, there was no clear association between SES and 
overall CRC incidence rates.
When stratifying the race-/ethnicity-specific analyses by cancer subsite, the direction of 
association for nonHispanic Whites remained consistent (inverse association); however, the 
IRR was lower when comparing highest to lowest SES level for left-sided (IRRSES Q5 v. Q1 = 
0.77; 95% CI: 0.72-0.83) than for right-sided tumors (IRRSES Q5 v. Q1 = 0.91; 95% CI: 
0.85-0.97). For rectal cancer, there was also a strong inverse association (IRRSES Q5 v. Q1 = 
0.71; 95% CI: 0.65-0.76). For African Americans, the inverse association between SES and 
CRC incidence was significant for left-sided colon cancer (IRRSESQ5 v. Q1 = 0.72; 95%CI: 
0.52-0.97) but not for right-sided colon or rectal cancer. For Hispanics, the positive 
associations between SES and colon cancer were seen for all subsites, but the effect estimate 
was stronger for right-sided (IRRSES Q5 v. Q1 = 1.85; 95% CI: 1.58-2.16) than for left-sided 
cancers (IRRSES Q5 v. Q1 = 1.50; 95% CI: 1.25-1.79) or rectal cancers (IRRSES Q5 v. Q1 = 
1.34; 95% CI: 1.12-1.59). For Asians/Pacific Islanders, a positive association was suggested 
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between SES and the incidence rate of right-sided colon cancer, yet no significant 
association was seen in left-sided colon or rectal tumors.
When comparing incidence rates between left- and right-sided colon cancers within each 
level of SES (Table 2), incidence rates of right-sided colon cancer were generally higher 
than the left-sided incidence rates. This pattern was similar across all racial/ethnic groups 
with the exception of Asians/Pacific Islanders for which incidence rates were higher for left-
sided colon tumors than for right-sided tumors. Notably, among non-Hispanic Whites a 
consistent pattern of an inverse association between SES and CRC incidence was seen 
across subsite, although for Hispanics a positive association was observed for left-sided, 
right-sided, and rectal tumors.
In stage-stratified analysis (Table 3), a significant positive association was observed between 
CRC incidence and SES for localized disease most consistently among Hispanics. For 
regional/metastasized disease, no overall association between CRC incidence and SES was 
observed. Inverse patterns of association were observed for non-Hispanic Whites and 
African Americans, whereas for Hispanics a positive association was found.
SES and CRC mortality
Characteristics of the 14,515 CRC patients who died between 1999 and 2001 are described 
in Table 4. Approximately 74.0% of the CRC patients were non-Hispanic Whites, 10.8% 
Hispanics, 8.0% African Americans, and 7.5% Asians/Pacific Islanders. A total of 14% of 
patients were in the lowest SES category and approximately 21% were in each of the other 
quintiles.
Mortality rates of CRC varied across race/ethnicity categories with highest rates among 
African Americans followed by non-Hispanic Whites, Hispanics, and Asians/Pacific 
Islanders (Table 5). In addition, mortality rates for colon cancer were consistently higher 
than that of rectal cancer, irrespective of ethnicity. Overall, reduced mortality rates of total 
CRC were associated with higher levels of SES (MRRSES Q 5 v. Q1 = 0.89;95% CI0.84–0.94; 
Table 5).This inverse pattern of association was seen for both deaths of colon and rectal 
cancers. Distinct patterns of associations were seen across the different racial/ethnic groups. 
For non-Hispanic Whites, mortality rates of CRC decreased significantly with higher levels 
of SES (MRRSES Q5 v. Q1 = 0.76; 95% CI 0.71-0.82). For African Americans, a similar 
nonsignificant inverse trend was observed. In contrast, a significant positive association 
between SES and CRC mortality was seen for Hispanics (MRRSES Q5 v. Q1 = 1.40; 95% 
1.14-1.71). For Asians/Pacific Islanders, mortality rates for CRC were not significantly 
associated with SES. Similar patterns of ethnic-specific associations were observed for both 
colon and rectal cancers.
Discussion
In this large population-based study of CRC patients, there were no overall associations 
between SES and CRC incidence rates; but rates differed by race/ethnicity and anatomical 
site. In ethnic-specific analyses, a positive association between CRC incidence rates and 
SES level was seen only among Hispanics; whereas among non-Hispanic Whites and 
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African Americans inverse associations were observed and no associations were seen for 
Asians/Pacific Islanders. Mortality rates of overall CRC were lower among patients at higher 
levels of SES. Yet, this inverse association was restricted to non-Hispanic Whites, whereas a 
positive association was seen among Hispanics.
Previous studies conducted in the United States and Canada (3) support our findings of 
lower incidence rates of CRC observed among those at higher levels of SES among non-
Hispanic Whites and African Americans. This may be attributed to common CRC risk 
factors, such as physical inactivity, obesity, or unhealthy diet choices (21), which have been 
reported to be more prevalent among low SES populations (22, 23). In addition, utilization 
and access to health care among non-Hispanic Whites and African Americans, in particular, 
participation in CRC screening programs, may play an important role. With increased 
opportunity for screening among those at higher levels of SES, early detection and removal 
of precancerous adenoma polyps may lead to lower disease rates among those of higher 
SES. Data from the California Health Interview Survey (2001) indicate that 55% of non-
Hispanic Whites and 54% of African Americans over 50 years of age received a fecal occult 
blood test, sigmoidoscopy, or colonoscopy within the past 5 years with higher screening 
rates seen with increasing household income and education (24, 25). In comparison, lower 
screening rates for Hispanics and Asians/Pacific Islanders (36% and 43%, respectively) were 
observed (24, 25). Having health insurance has been associated with higher screening rates 
(26), and physicians have been found to be less likely to discuss screening with patients of 
lower education (27). Furthermore, barriers in CRC screening, such as fear of injury, are 
more frequently reported in low SES subjects than in those of high SES (26). Thus, greater 
acceptance and utilization of CRC screening among higher SES non-Hispanic Whites and 
African Americans may contribute to the inverse association between SES and CRC.
Conversely, among Hispanics higher incidence rates of CRC were associated with higher 
levels of SES. Higher SES Hispanics may be more acculturated and adopt a more 
“westernized lifestyle” of physical inactivity, obesity, increased red meat consumption, and 
other health behaviors that serve as CRC risk factors (21). Supporting this hypothesis are 
subanalyses of a neighborhood ethnic enclave index (composed of language and 
immigration-related census variables; 28-30), in which we found that Hispanics living in 
more acculturated neighborhoods had higher incidence rates of CRC than those living in 
lower acculturation neighborhoods (highest to lowest quintile incidence rate per 100,000: Q5 
= 148.7; Q4 = 138.7; Q3 = 131.6; Q2 = 118.3; Q1 = 94.9; data not shown).
For Asians/Pacific Islanders, we did not find clear associations between SES and CRC 
incidence, which might in part be attributed to the heterogeneous composition of this racial/
ethnic group. A recent study on CRC incidence trends based on data from the CCR indicated 
that despite decreasing trends in CRC incidence for Asians/Pacific Islanders overall, the 
incidence is actually increasing for some subgroups (31).
In the United States, CRC incidence trends in 1980s and 1990s have shown a decline in rates 
of left-sided colon cancer whereas right-sided cancer rates remained unchanged (7). Data 
from 2000 onward show a decline in right-sided tumors although less steep than for left-
sided tumors (32). Besides a differing role of genetic and environmental risk factors in left- 
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versus right-sided tumor development, screening procedures might account for the 
difference in site-specific trends (7, 32) because left-sided colon cancer has been seen to be 
more likely screen detected than right-sided tumors (33). With higher SES reported to be 
associated with higher screening rates (14-16), we investigated whether the distribution of 
tumor subsite varied across SES levels. For left-sided colon cancer, SES was inversely 
associated with incidence of disease, where-as for right-sided colon cancer a positive 
association was observed. In ethnic-specific analyses, the inverse association between SES 
and colon cancer was more pronounced for left-sided than for right-sided tumors among 
Non-Hispanic Whites and African Americans, pointing to a stronger role of SES in left-
sided tumors.
The reduced mortality rates of CRC associated with higher levels of SES is likely 
attributable to better health care access, informed education on health promoting behaviors, 
and avoidance of high-risk behaviors (34). Furthermore, greater screening participation seen 
in higher SES groups (14) allow for the removal of polyps and the detection of early stage 
disease (35). Racial/ethnic differences in the association between SES and CRC mortality 
were evident with a significant inverse association seen in non-Hispanic Whites although a 
significant positive association was observed among Hispanics.
Prior studies have similarly found that U.S. Hispanics have lower mortality rates than non-
Hispanic Whites, despite lower income and less education (36-38). Possible explanations for 
this “Hispanic paradox” (38) has been attributed to healthier Latinos migrating to the United 
States, the return of Hispanics to their native country to die in one’s birthplace, and/or better 
social support resulting in improved health outcomes. Studies of cancer survival in 
Californian Hispanics indicate that a higher percentage of foreign-born Hispanics leave the 
country for medical care than U.S.-born Hispanics (29, 39). However, this migration effect 
may be too small to completely account for the Hispanic paradox (40). Additional studies of 
cancer survival in Hispanics with active follow-up and well-characterized information on 
place of birth are needed to clarify these observations.
Strengths of our study include the large multiethnic population, representing the diversity of 
the state of California and the use of census tracts as smallest geographic units, which are 
more homogeneous with regard to SES than larger geographic units such as counties. The 
use of area-based measures of SES allow for capturing elements of the socioeconomic 
environment that might not be attainable by individual-level data (41). Our comprehensive 
measure of SES included several domains of SES (e.g., education, income, employment) in 
contrast to using a single SES domain. We recognize that various SES measures may 
conduct differently across racial/ethnic groups such that within the same level of SES, 
individuals from different ethnic groups may not share the same level of power, prestige, and 
opportunities (19).
There are limitations to our study. For some subanalyses, the number of cases for some rates 
was small, especially among African Americans, leading to unstable associations. 
Furthermore, our grouping of different Asian populations and Pacific Islanders into one 
racial/ethnic category may not accurately reflect the associations seen in specific 
subpopulations. The cross-sectional design of this study and use of area-level neighborhood 
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SES data in the absence of individual-level data limits the consideration of health behaviors 
and confounders that may further clarify the observed associations. In addition, ecologic 
fallacy may occur when area-level measures of SES do not accurately reflect individual 
levels of SES. Finally, we used the 2000 U.S. population counts to calculate population 
denominators for intercensal years, which may not represent the true population size of the 
incidence and mortality periods of analysis.
In conclusion, this study shows that the impact of SES on CRC incidence and mortality rates 
differs across racial/ethnic groups. These associations inform future studies having detailed 
individual-level data on health behaviors, screening, biologic markers as well as area-level 
measures of the contextual features of the neighborhood environment to comprehensively 
disentangle these complex interrelationships.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Characteristics of incident CRC cases, California 1998-2002
Total CRC (n = 52,608) 
n (%)
Right-sided colon 
cancer (n = 20,560) n 
(%)
Left-sided colon cancer 
(n = 14,969) n (%)
Rectal cance (n = 
14,828) N (%)
Age group
 50–59 years   9,141 (17.4)   2,528 (12.3)   2,908 (19.4)   3,467 (23.4)
 60–69 years 12,944 (24.6)   4,464 (21.7)   3,989 (26.6)   4,116 (27.8)
 70–79 years 17,024 (32.4)   7,089 (34.5)   4,853 (32.4)   4,468 (30.1)
 80+ years 13,499 (25.7)   6,479 (31.5)   3,219 (21.5)   2,777 (18.7)
Male 26,681 (50.7)   9,179 (44.6)   8,067 (53.9)   8,399 (56.6)
Female 25,927 (49.3) 11,381 (55.4)   6,902 (46.1)   6,429 (43.4)
Race/ethnicity
 Non-Hispanic White 37,407 (71.1) 15,247 (74.2) 10,204 (68.2) 10,293 (69.4)
 African American   3,475 (6.6)   1,505 (7.3)   1,039 (6.9)      756 (5.1)
 Hispanic   6,427 (12.2)   2,257 (11.0)   1,856 (12.4)   2,050 (13.8)
 Asian/Pacific Islander   5,299 (10.1)   1,551 (7.5)   1,870 (12.5)   1,729 (11.7)
Tumor stage
 Localized 17,482 (33.2)   5,983 (29.1)   5,561 (37.2)   5,835 (39.4)
 Regional/metastasized 29,147 (55.4) 12,777 (62.1)   8,167 (54.6)   7,264 (49.0)
 Unknown   5,958 (11.3)   1,800 (8.8)   1,241 (8.3)   1,729 (11.7)
Tumor grade
 Well differentiated   4,691 (8.9)   1,691 (8.2)   1,653 (11.0)   1,290 (8.7)
 Moderately differentiated 30,853 (58.6) 11,983 (58.3)   9,540 (63.7)   9,007 (60.7)
 Poorly differentiated   8,846 (16.8)   4,709 (22.9)   1,929 (12.9)   2,037 (13.7)
 Unknown   8,218 (15.6)   2,177 (10.6)   1,847 (12.3)   2,494 (16.8)
SES quintile
 Q1 (lowest)   7,226 (13.7)   2,632 (12.8)   2,170 (14.5)   2,092 (14.1)
 Q2 10,624 (20.2)   3,997 (19.4)   3,032 (20.3)   3,065 (20.7)
 Q3 11,414 (21.7)   4,423 (21.5)   3,187 (21.3)   3,298 (22.2)
 Q4 11,814 (22.5)   4,803 (23.4)   3,236 (21.6)   3,299 (22.2)
 Q5 (highest) 11,530 (21.9)   4,705 (22.9)   3,344 (22.3)   3,074 (20.7)
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